MACI not checked

Vericel Corporation

FollowEvery change as it happens, and a Monday email
Stage
in the US and EU
Next date
Phase 3 trial completes
Trials
2 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“autologous cultured chondrocytes on porcine collagen membrane”In the company’s words, NCT03588975 on ClinicalTrials.gov
Tested for
Chondral Defect (2 trials), Articular Cartilage Defect (2 trials), Osteochondritis Dissecans (OCD), Articular Cartilage Disorder of Knee
Main trialPhase 3
“The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.”In the company’s words, NCT03588975 on ClinicalTrials.gov

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Feb 2030 A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Phase 3Recruiting Jul 2030 A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
Phase 3Completed Mar 2012 Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow MACI

Following is part of Solo: you see every change to MACI the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in